Please rotate your device to landscape

For the best learning experience, we recommend to use a desktop device.

The benefits of early DMT in relapsing–remitting MS

Learning objectives

This module was produced during the 2021 quarantine, where filming has been conducted remotely to adhere to social distancing guidelines. For this reason, please forgive a lower production quality than you are used to seeing from us.

This module is intended to help you:

Cite data on the probability of functional deficits in early disease
Understand the relationship between time from symptom onset to treatment and long-term outcomes
Cite international recommendations and clinical standards for diagnosis and referral
Implement steps that can improve communication with patients about the need for early therapy

The benefits of early DMT in relapsing–remitting MS

There is established evidence that early treatment with disease-modifying therapies improves outcomes for people with MS. This module discusses these data and considers how the diagnosis and management of people with MS can be optimised to deliver timely treatment.

Length
13 min course

Job code
NPS-TPE-NP-00174

Long-term follow-up analyses of clinical trials have shown that, compared with later start, early start of platform therapy is associated with benefits in terms of...

Select the correct answer(s)

Patients who received early therapy rather than late DMT were more likely to have a stable or improved EDSS and a lower risk of requiring a walking aid.^1,2 Further studies have shown improvement in MRI lesion load and relapse rate.³

According to the EAN/ECTRIMS guidelines, when should injectable platform therapies be offered?

Select the correct answer(s)

Injectable platform therapies should be offered in
patients with CIS and an abnormal MRI with lesions suggestive of MS who do not fulfil criteria for MS.¹

Which of these factors are associated with diagnostic delay in MS?

Select the right answer(s)

Which of these are medical specialists that support the core MS Care Team, but are not directly included in it?

Select the correct answer(s)

When involved in treatment decisions, are patients with mild disease more
or less risk averse towards adverse
events compared with patients with
active disease?

Select the correct answer(s)

When involved in treatment decisions, patients with mild disease are more likely than those with active disease to select DMTs with low risk of adverse events.¹

The benefits of early DMT in relapsing–remitting MS

Please note you are now leaving Neurologybytes.com and being redirected to a different website not operated by Teva Pharmaceuticals.

Please rotate your device to landscape

For the best learning experience, we recommend to use a desktop device.

The benefits of early DMT in relapsing–remitting MS

Learning objectives

The proportion of patients with cognitive impairment with RIS or RRMS

Compared with the proportion of patients with cognitive impairment in RIS (n=29) (subclinical), the proportion of patients with cognitive impairment with RRMS (n=26) is considered to be…

Select the correct answer(s)

Gadolinium-enhanced MRI scans for Cases A and B

These 2 case studies both have EDSS 2.0 and have been diagnosed with MS. According to the guidelines, which of these patients should be offered DMT?

Select the correct answer(s)

Long-term follow-up analyses of clinical trials have shown that, compared with later start, early start of platform therapy is associated with benefits in terms of...

Select the correct answer(s)

Patients who received early therapy rather than late DMT were more likely to have a stable or improved EDSS and a lower risk of requiring a walking aid.1,2 Further studies have shown improvement in MRI lesion load and relapse rate.3

According to the EAN/ECTRIMS guidelines, when should injectable platform therapies be offered?

Select the correct answer(s)

Injectable platform therapies should be offered in patients with CIS and an abnormal MRI with lesions suggestive of MS who do not fulfil criteria for MS.1

Which of these factors are associated with diagnostic delay in MS?

Select the right answer(s)

Which of these are medical specialists that support the core MS Care Team, but are not directly included in it?

Select the correct answer(s)

When involved in treatment decisions, are patients with mild disease more or less risk averse towards adverse events compared with patients with active disease?

Select the correct answer(s)

When involved in treatment decisions, patients with mild disease are more likely than those with active disease to select DMTs with low risk of adverse events.1

Congratulations!

You have completed module 6

Links and downloadable elements

The benefits of early DMT in relapsing–remitting MS

Disability progression

Vaccination and MS

Patients who received early therapy rather than late DMT were more likely to have a stable or improved EDSS and a lower risk of requiring a walking aid.^1,2 Further studies have shown improvement in MRI lesion load and relapse rate.³

Injectable platform therapies should be offered in
patients with CIS and an abnormal MRI with lesions suggestive of MS who do not fulfil criteria for MS.¹

When involved in treatment decisions, are patients with mild disease more
or less risk averse towards adverse
events compared with patients with
active disease?

When involved in treatment decisions, patients with mild disease are more likely than those with active disease to select DMTs with low risk of adverse events.¹